Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case

24 Oct 2014

• By Emily Hayes

Related Content

Rituxan Market Expansion In Rheumatoid Arthritis Patients Sidelined By PML Risk

19 Oct 2009

Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

13 Apr 2009

Legacy Cost: Takeda’s <em>Entyvio</em> Development Shaped By <em>Tysabri</em> Fallout

24 Oct 2014

Related Companies

Biogen, Inc.

Roche Holding AG

Additional Topics

Safety Risk Management BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.